Roche opens its doors to employees’ children on National Future Day

Basel, 07 November 2012

Youngsters can spend a day at work with their parents and experience the fascinating world of pharmaceutical research and development

On 8 November Roche will open its doors to young people aged 10 to 16 and providing them with an inside look at the wide range of jobs and career paths that Roche can offer.

“We hope the day will be a great experience for our employees’ sons and daughters, and that we’ll be able to generate some excitement and curiosity about careers in pharmaceuticals and diagnostics,” said Matthias M. Baltisberger, Head of Roche Basel. “We want each of our young visitors to come away with greater confidence in themselves and their ability to pursue career choices regardless of background and gender. ”

A special event entitled From Molecule to Medicine will provide a vivid, engaging look at what molecules are and how promising chemical compounds become medicines. There will also be interactive learning events on topics ranging from nutrition, chemistry and biology to pharmaceutical formulation. Roche’s young visitors will be able to construct molecules, pipette solutions and press tablets. They will also be given information on vocational training opportunities.

How Roche fosters new talent

Roche believes in fostering talent, which is why it provides top-class training to young people in around 400 apprenticeships at its sites in Switzerland. In addition, about 250 students complete an internship each year, and over 1000 schoolchildren and students benefit from guided tours and educational presentations that offer insights into the company’s many activities. Through its continued support for foundations such as Simply Science, Swiss Youth in Science (SJf) and SJf’s Swiss Talent Forum, Roche enables young people to test their creativity as they discover how much art, science and technology have in common.

About Roche

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2011, Roche had over 80,000 employees worldwide and invested over 8 billion Swiss francs in R&D. The Group posted sales of 42.5 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com